AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 291 min read$MNPR

Robinson Chandler sold $2.6M of MNPR

Robinson Chandler (Chief Executive Officer) sold 29,056 shares of Monopar Therapeutics (MNPR) at an average of $88.00 ($87.15–$89.79, $2.56M total) across 4 trades on 2026-09-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Robinson Chandler
Published Sep 29, 2026, 12:47 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 2:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MNPR
Bearish
medium confidence
Mentioned
$MNPR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MNPRBearishLow
01

Why it matters

The CEO's sale could trigger short‑term price decline, but the pre‑arranged nature may limit long‑term impact.

02

Market read

Insider sell of $2.5M by the CEO may prompt modest downside for MNPR.

03

What to watch

Pre‑arranged plan execution timing and possible tax or liquidity needs.

Relevance 5/10Novelty 6/10Timing: after-hours

Background

Form 4 filing discloses insider transactions, a primary source for corporate insider activity.

Company-level read

Ticker impact

$MNPRBearishMedium confidence
Context

CEO Robinson Chandler sold 29,056 shares for $2.56M via a 10b5-1 plan, reducing his stake to 99,267 shares.

Expected impact

likely downward pressure as market prices in the insider sell.

Evidence & confidence

A $2.5M sale by the CEO, even under a pre‑arranged plan, can be interpreted as reduced confidence, prompting short‑term sell‑offs.

Market effects

Sector

Biotech sector may see slight sell pressure from insider activity.

Regional

US equity markets

Global

Limited to investors tracking MNPR

Counterpoint

What could challenge this read

Sale may be routine under a 10b5-1 plan and not indicate fundamental weakness.

Key entities

  • person
    Robinson Chandler

    Chief Executive Officer of Monopar Therapeutics

  • company
    Monopar Therapeutics

    Biotech firm listed on Nasdaq under ticker MNPR

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MNPR insider trading history →

Related articles

AUG 12
$MNPRLow

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Wilmette, IL, August 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative tr

SEC EDGAR 8-K2 min
JUN 1
$MNPRMedAI 8/10

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

Monopar Therapeutics presented Phase 2 ALXN1840 (tiomolibdate choline) data at EASL 2026 for treatment-experienced Wilson disease patients. In an open-label, multicenter 48-week trial (29 patients; 24 with paired biopsies), histology showed stabilization or improvement in multiple liver measures, with no statistically significant change in hepatic copper. The company also reported significant improvements in UWDRS Part III, CGI, and EQ-5D UK, with generally nonserious Grade 1–2 adverse events.

manilatimes.net4 min
OCT 7
$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $2.2M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 103,684 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $20.92 ($20.80–$21.09, $2.17M total) across 3 trades over 2026-10-02 to 2026-10-06. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Zolezzi William (10% owner), Divisadero Street Partners, L.P. (10% owner) and Divisadero Street Capital, LLC (10% owner).

SEC EDGAR1 min